Aims:
To investigates the stability of ATZ along with PIP under different stress conditions and characterization of degradants by LC-QTOF-ESI-MS including in-vitro cellular anticancer activity, in-vivo pharmacokinetics, and biodistribution studies.
Background::
Anastrozole (ATZ) is being widely used in the treatment of breast cancer and it requires a high dose while long-term medication. ATZ high dose may kill the non-cancerous cells also and leads towards multidrug resistance (MDR) due to efflux of P-Glycoprotein. ATZ is reported for poor water solubility and lesser oral bioavailability. Piperine (PIP) has been reported to enhance the various pharmacokinetic parameters like bioavailability of various active pharmaceutical ingredients and phytoconstituents. PIP is known to inhibit drug transporter P-glycoprotein. PIP stops drug metabolism by inhibiting the action of P450/CYP3A4.
Objective:
To explore the stability studies of ATZ along with PIP in different stress conditions. it was also proposed to perform the characterization of degradants by LC-QTOF-ESI-MS including in-vitro cellular anticancer activity, in-vivo pharmacokinetics, and biodistribution studies.
Method:
Degradants were identified for molecular weight using LC-QTOF-ESI-MS and structures of degradants were confirmed by fragmentation pattern along with mass accuracy measurements. Pharmacokinetic and biodistribution were performed using Wistar rat and calculated Pharmacokinetic parameters for ATZ, PIP, and their combination. The validated method was used for stressed studies as well as bioanalytical.
Result:
A total of fourteen degradants were characterized. ATZ and PIP have shown synergistic anticancer effects in the 4T1 cell line and shown superior Pharmacokinetic and biodistribution with good oral absorption and high bioavailability.
Conclusion:
Therefore, there is huge scope in the future to conduct pharmacological and formulation studies for this combination.